Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

Maria Dinche Johansen; Thomas Urup; Camilla Bjørnbak Holst; Ib Jarle Christensen; Kirsten Grunnet; Ulrik Lassen; Søren Friis; Hans Skovgaard Poulsen

doi:10.1080/07357907.2018.1544639

Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

Maria Dinche Johansen, Thomas Urup, Camilla Bjørnbak Holst, Ib Jarle Christensen, Kirsten Grunnet, Ulrik Lassen, Søren Friis, Hans Skovgaard Poulsen

Abstrakt

PURPOSE: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.

METHODS: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).

RESULTS: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).

CONCLUSIONS: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.

Originalsprog	Engelsk
Tidsskrift	Cancer Investigation
Vol/bind	36
Udgave nummer	9-10
Sider (fra-til)	512-519
Antal sider	8
ISSN	0735-7907
DOI	https://doi.org/10.1080/07357907.2018.1544639
Status	Udgivet - 2018

Adgang til dokumentet

10.1080/07357907.2018.1544639

Citationsformater

@article{894868614dd54c95a9d8bba20b2dfbd0,

title = "Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors",

abstract = "PURPOSE: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.METHODS: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).RESULTS: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).CONCLUSIONS: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.",

author = "Johansen, {Maria Dinche} and Thomas Urup and Holst, {Camilla Bj{\o}rnbak} and Christensen, {Ib Jarle} and Kirsten Grunnet and Ulrik Lassen and S{\o}ren Friis and Poulsen, {Hans Skovgaard}",

year = "2018",

doi = "10.1080/07357907.2018.1544639",

language = "English",

volume = "36",

pages = "512--519",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "9-10",

}

TY - JOUR

T1 - Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

AU - Johansen, Maria Dinche

AU - Urup, Thomas

AU - Holst, Camilla Bjørnbak

AU - Christensen, Ib Jarle

AU - Grunnet, Kirsten

AU - Lassen, Ulrik

AU - Friis, Søren

AU - Poulsen, Hans Skovgaard

PY - 2018

Y1 - 2018

N2 - PURPOSE: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.METHODS: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).RESULTS: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).CONCLUSIONS: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.

AB - PURPOSE: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.METHODS: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).RESULTS: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).CONCLUSIONS: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.

U2 - 10.1080/07357907.2018.1544639

DO - 10.1080/07357907.2018.1544639

M3 - Journal article

C2 - 30727779

VL - 36

SP - 512

EP - 519

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 9-10

ER -

Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

Abstrakt

Adgang til dokumentet

Fingeraftryk

Citationsformater